A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03322007|
Recruitment Status : Not yet recruiting
First Posted : October 26, 2017
Last Update Posted : October 26, 2017
BACKGROUND: Pain is the predominant and most feared symptom of pancreas cancer, and is often incompletely relieved. Scrambler Therapy is a new way of treating pain by providing "non-pain" information to confuse the nervous system and reset the damaged nerve pathways. It has been useful in treating many types of pain, but has not been adequately tested in the pain associated with pancreas cancer.
OBJECTIVE: The goal of this study is to evaluate the effect of Scrambler Therapy on typical abdominal pain associated with pancreas cancer.
HYPOTHESIS: We hypothesize that pain scores from day 0 (pre) to day 28 (post) will be reduced by at least 33%, e.g. from 6/10 to 4/10.
METHODS: 20 patients, with expected data from 18 due to drop out of 2, will be treated with Scrambler Therapy using the standard methods of 45 minute sessions for 10 treatments.
OUTCOMES: We will record data using the Brief Pain Inventory, and EORTC Quality of Life Questionnaire-Pancreas 26 to see if we obtain at least a 33% reduction in pain. This will inform future randomized trials of Scrambler Therapy versus traditional methods such a celiac plexus blocks.
|Condition or disease||Intervention/treatment|
|Pain, Chronic||Device: Scrambler Therapy|
Specific aims include the following:
- To determine the change in pain from day 0 to day 28 with scrambler therapy in patients with pancreas cancer pain. (Question #3 of the Modified Brief Pain Inventory). This endpoint serves to get preliminary information on the effect size for planning future larger, phase III studies comparing to splanchnic or celiac nerve blocks. The primary measurement tool for pain will be the Brief Pain Inventory (BPI).
- To determine changes in the complete Brief Pain Inventory; changes in pain drug use; and changes in quality of life (QOL) using the EORTC QUALITY OF LIFE QUESTIONNAIRE-PANCREAS 26, our current Hopkins standard. With 18 patients and a one-sided type 1 error rate of 10%, we have 87% power to detect a 33% reduction in pain, the primary endpoint, and can complete this in one year. To ensure completion, we will enroll 20.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Single institution, single arm trial of Scrambler Therapy for Pancreas Cancer Pain|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer|
|Anticipated Study Start Date :||January 1, 2018|
|Estimated Primary Completion Date :||July 1, 2019|
|Estimated Study Completion Date :||September 2019|
Experimental: Open label treatment
Usual FDA-cleared pain management with Scrambler Therapy
Device: Scrambler Therapy
external neuromodulation to relieve pain; the device was cleared by the FDA in 2009 for safety, considering it like a TENS unit
Other Name: Calmare Therapy
- Brief Pain Inventory pain at day 28 [ Time Frame: 28 days ]usual or average pain that day, Q3 on BPI
- EORTC Quality of Life [ Time Frame: 28 days ]QOL standard for pancreas cancer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03322007
|Contact: Thomas J Smith, MD||410 955 email@example.com|
|Contact: Paula Eissmann, BA||410 955 firstname.lastname@example.org|
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21287-0013|
|Principal Investigator:||Thomas J Smith, MD||Sidney Kimmel Comprehensive Cancer Center|